MintNeuro is a technology company.
MintNeuro has raised $1.0M across 1 funding round.
MintNeuro has raised $1.0M in total across 1 funding round.
MintNeuro has raised $1.0M in total across 1 funding round.
MintNeuro's investors include Elbow Beach Capital.
MintNeuro is a deep-tech company developing purpose-built, ultra-low-power semiconductor chips for next-generation neural implants, enabling smaller, safer, and more scalable devices to treat neurological conditions like epilepsy, Parkinson's, dementia, depression, and urinary incontinence.[1][2][4] These chips integrate neural sensing, stimulation, signal processing, power management, and wireless communication, serving medical device companies, researchers, and consortia to create minimally invasive implants that reduce surgery needs and development costs.[2][4][5] With roots in over a decade of Imperial College London research and £1M in recent investment plus £14M in grants, MintNeuro shows strong growth through partnerships like Amber Therapeutics and ARIA-funded projects.[4][7]
MintNeuro spun out from Imperial College London's bioelectronics lab in 2022, building on 10-15 years of UKRI-funded research in ultra-low-power implantable devices.[3][5][7] Co-founders include CEO Dr. Dorian Haci, who joined the team eight years prior as a student and progressed to postdoctoral researcher and Royal Academy of Engineering Enterprise Fellow, and CTO Timothy Constandinou, a professor whose lab identified gaps in bulky, power-hungry neural electronics.[2][4][5][7] The idea emerged from observing that existing implants required major surgery and high costs due to outdated components; the team licensed core IP from Imperial to create peppercorn-sized chips for precise, long-term brain interfaces.[3][5] Early traction includes £14M in R&D grants, a £1M investment round, and partnerships validating sensing for epilepsy monitoring.[4][5][7]
MintNeuro stands out through its modular, semiconductor-first approach to neural implants:
MintNeuro rides the neurotech revolution, intersecting semiconductors, biotech, and bioelectronics to address limitations in bulky implants amid rising demand for precise therapies for neurological disorders affecting millions.[1][2][3] Timing aligns with Europe's push for strategic autonomy in microchips, reducing foreign dependency while enabling dual-use potential in defense (e.g., soldier resilience) and medicine.[3] Market forces like ARIA's Precision Neurotechnologies funding and partnerships with global players (e.g., Motif Neurotech, Rice University) amplify its influence, positioning it as a key enabler in the UK/EU ecosystem for affordable, ubiquitous brain therapies.[4][7] By providing foundational hardware, MintNeuro accelerates adoption of brain-computer interfaces and neuromodulation, transforming last-resort treatments into elective options.[5]
MintNeuro is poised to scale via ongoing validations in epilepsy sensing and neuromodulation, with chipset expansions to Parkinson's, dementia, depression, and neuropsychiatric disorders through ARIA projects and commercial partnerships.[4][5][7] Trends like AI-driven neural processing, wireless miniaturization, and regulatory tailwinds for low-power implants will propel growth, potentially capturing share in a market hungry for non-invasive alternatives. Its influence may evolve from chip supplier to platform leader, fostering a vibrant neurotech ecosystem—echoing its origin as a fix for "chips that weren't good enough," now redefining scalable brain therapies.[2]
MintNeuro has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $1.0M Seed | Elbow Beach Capital |